{"raw_mentions": "There are no sentences that meet the specified criteria. The text does not contain specific molecule names, IDs, or identifiers along with bioactivity metrics (IC50, Ki, Kd, EC50), numeric values, and units. The text primarily describes the structure and content of tables and methods used in an assay, without providing specific data that includes all four required components."}
{"raw_mentions": "There are no sentences that contain all four required components: a specific molecule name, ID or other identifier, a bioactivity metric (IC50, Ki, Kd, EC50 and their variations), a specific numeric value for that metric, and a unit for that value. The text snippet provided appears to describe protein sequences and potential targeting of PDZ domain-containing proteins but does not include bioactivity metrics with specific numeric values and units."}
{"raw_mentions": "There are no sentences that meet the specified criteria, as none of the sentences contain a specific molecule name, a bioactivity metric (IC50, Ki, Kd, EC50), a numeric value for that metric, and a unit for that value. The text appears to describe protein sequences and their potential interactions with PDZ domain-containing proteins, but does not provide any quantitative bioactivity data."}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nat step (2) the peptide concentration is 10 uM instead of 20 uM.\nThe \"G' ' assay\" is identical to the \"G\u00b0 assay\" except that at step (2) the peptide concentration is 1 uM instead of 20 uM \n(Entropies and enthalpies are related to binding affinity by the equations delta G = RT In (Kd) = delta H - T delta S where delta G, H, and S are the reaction free energy, enthalpy, and entropy respectively, T is the temperature in degrees Kelvin, R is the gas constant, and Kd is the equilibrium dissociation constant)."}
{"final_json": [{"molecule_name": null, "protein_target_name": null, "binding_metric": null, "value": "10", "unit": "uM"}, {"molecule_name": null, "protein_target_name": null, "binding_metric": null, "value": "1", "unit": "uM"}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "Kd", "value": null, "unit": null}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nTABLE 8 is added to the surface in increasing concentrations in PBS/BSA (e.g. at 0.1 uM, 0.33 uM, 1 uM, 3.3 uM, 10 uM, 33 uM, and 100 uM).\nIn cases where satisfying the above criteria proves difficult, an alternative approach (infra) can be used, peptide concentrations are 0.1 uM, 1 uM, 10 uM, 100 uM, 1 mM.\nThe PDZ-ligand binding signal is plotted as a function of ligand concentration and the plot is fit. (e.g., by using the Kaleidagraph software package curve fitting algorithm) to the following equation, where \"Signal<sub>[Ligand]</sub>\" is the binding signal at PL peptide concentration \"[ligand],\" \"Kd\" is the apparent affinity of the binding event, and \"Saturation Binding\" is a constant determined by the curve fitting algorithm to optimize the fit to the experimental data:"}
{"final_json": [{"molecule_name": null, "protein_target_name": null, "binding_metric": null, "value": "0.1", "unit": "uM"}, {"molecule_name": null, "protein_target_name": null, "binding_metric": null, "value": "0.33", "unit": "uM"}, {"molecule_name": null, "protein_target_name": null, "binding_metric": null, "value": "1", "unit": "uM"}, {"molecule_name": null, "protein_target_name": null, "binding_metric": null, "value": "3.3", "unit": "uM"}, {"molecule_name": null, "protein_target_name": null, "binding_metric": null, "value": "10", "unit": "uM"}, {"molecule_name": null, "protein_target_name": null, "binding_metric": null, "value": "33", "unit": "uM"}, {"molecule_name": null, "protein_target_name": null, "binding_metric": null, "value": "100", "unit": "uM"}, {"molecule_name": null, "protein_target_name": null, "binding_metric": null, "value": "0.1", "unit": "uM"}, {"molecule_name": null, "protein_target_name": null, "binding_metric": null, "value": "1", "unit": "uM"}, {"molecule_name": null, "protein_target_name": null, "binding_metric": null, "value": "10", "unit": "uM"}, {"molecule_name": null, "protein_target_name": null, "binding_metric": null, "value": "100", "unit": "uM"}, {"molecule_name": null, "protein_target_name": null, "binding_metric": null, "value": "1", "unit": "mM"}, {"molecule_name": "PL peptide", "protein_target_name": "PDZ", "binding_metric": "Kd", "value": null, "unit": null}]}
{"raw_mentions": "Unfortunately, there are no sentences in the provided text that contain all four required components: a specific molecule name, ID or other identifier, a bioactivity metric (IC50, Ki, Kd, EC50), a specific numeric value for that metric, and a unit for that value. \n\nHowever, I can provide some sentences that contain some of the required components, but not all:\n\n* The Kd measurement of PDZ-PL binding as determined using the methods supra can be used in determining Ki.\n* For example, administration of an inhibitor of a PDZ-PL interaction in an amount sufficient to result in an intracellular inhibitor concentration of at least between about 1 and about 100 Ki is expected to inhibit the biological response mediated by the target PDZ-PL interaction.\n* The Ki of the binding can be calculated by any of a variety of methods routinely used in the art, based on the amount of ligand bound in the presence of different concentrations of the inhibitor.\n* The concentrations of the test inhibitor typically range from 1 nM to 100 uM (e.g. a 4-fold dilution series with highest concentration 10 uM or 1 mM).\n* The ligand is typically present at a concentration of less than 2 Kd (e.g., between about 0.01 Kd and about 2 Kd).\n* The concentrations of the test agent/enhancer typically range from 1 nM to 1 mM (e.g. a 4-fold dilution series with highest concentration 10 uM or 1 mM).\n* Typical therapeutic concentrations are between about 0.1 and about 100 K<sub>enhancer</sub>.\n\nPlease note that these sentences do not meet the criteria as they are missing one or more of the required components."}
{"final_json": [{"molecule_name": null, "protein_target_name": "PDZ-PL", "binding_metric": "Kd", "value": null, "unit": null}, {"molecule_name": null, "protein_target_name": "PDZ-PL", "binding_metric": "Ki", "value": null, "unit": null}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "Ki", "value": null, "unit": null}, {"molecule_name": null, "protein_target_name": null, "binding_metric": null, "value": "1", "unit": "nM"}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "Kd", "value": "<2", "unit": null}, {"molecule_name": null, "protein_target_name": null, "binding_metric": null, "value": "1", "unit": "nM"}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "Kenhancer", "value": "0.1", "unit": null}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* An optimal inhibitor of a particular function (e.g., including but not limited to an anti-chemotactic agent, an anti-T cell activation agent, cell-cycle control, vesicle transport, apoptosis, etc.) will inhibit multiple PDZ-ligand interactions involved in the function (e.g., chemotaxis, activation) but few other interactions, thus, the assay is used in one embodiment in screening and design of a drug that specifically blocks a particular function, for example, an agent designed to block chemotaxis might be identified because, at a given concentration, the agent inhibits 2 or more PDZs involved in chemotaxis but fewer than 3 other PDZs, or that inhibits PDZs involved in chemotaxis with a Ki > 10-fold better than for other PDZs.\n* For each PDZ protein (or as many as possible), identify the cognate PL(s) bound by the PDZ protein; c) Determine the Ki at which the test agent inhibits each PDZ-PL interaction, using the methods described supra; \n* An agent designed to block chemotaxis might be identified because, at a given concentration, the agent inhibits 2 or more PDZs involved in chemotaxis but fewer than 3 other PDZs, or that inhibits PDZs involved in chemotaxis with a Ki > 10-fold better than for other PDZs."}
{"final_json": [{"molecule_name": null, "protein_target_name": "PDZ", "binding_metric": "Ki", "value": "> 10-fold", "unit": null}, {"molecule_name": null, "protein_target_name": "PDZ protein", "binding_metric": "Ki", "value": null, "unit": null}, {"molecule_name": null, "protein_target_name": "PDZ", "binding_metric": "Ki", "value": "> 10-fold", "unit": null}]}
{"raw_mentions": "There are no sentences that meet the specified criteria. The text does not contain specific molecule names, IDs, or identifiers along with bioactivity metrics (IC50, Ki, Kd, EC50) and their corresponding numeric values with units."}
{"raw_mentions": "None"}
{"raw_mentions": "There are no sentences that contain all four required components: a specific molecule name, ID or other identifier, a bioactivity metric (IC50, Ki, Kd, EC50), a specific numeric value for that metric, and a unit for that value. The text appears to be focused on cloning and sequencing of various constructs, but does not include any information on bioactivity metrics."}
{"raw_mentions": "There are no sentences that meet the specified criteria. The text does not contain any sentences with a specific molecule name, a bioactivity metric (IC50, Ki, Kd, EC50), a numeric value, and a unit. The text appears to be describing methods and procedures for cloning, purification, and analysis of peptides and proteins, but does not provide specific data or measurements that meet the criteria."}
{"raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n* Comparing dissociation constants (.006 uM for Tax:TIP-l, 20 uM for CD95:TIP-1), one can see that Tax can bind TIP-1 >3000-fold more strongly than CD95.\n* TABLE 4 shows the Kd values in uM for the interactions between proteins and peptides in a series of 'G-Assay' experiments.\n* Values beneath each ligand indicate first the maximum absorbance followed by the observed Kd in uM.\n* FIGURE 2B shows that 20, 100, and 500 \u03bcM Tax is able to compete for binding to TLP-l with 20 \u03bcM labeled CD95.\n* FIGURE 2C shows that it takes 100-500 \u03bcM unlabeled CD95 peptide to compete for binding of 1 \u03bcM Tax to TIP-1."}
{"final_json": [{"molecule_name": "Tax", "protein_target_name": "TIP-1", "binding_metric": "Kd", "value": "0.006", "unit": "uM"}, {"molecule_name": "CD95", "protein_target_name": "TIP-1", "binding_metric": "Kd", "value": "20", "unit": "uM"}]}
{"raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe 50uM CD95 8-mer can successfully reduce binding of CLASP-2 and CD95 labeled ligand approximately 30% at only 2.5 to 5-fold excess.\nAs can be seen in TABLE 10A, agonist effects can be seen up to 4.3 fold higher than in the absence of drug, as in the case of AF6 and presenilin-1 in the presence of amitriptyline.\nAntagonistic effects have been demostrated here up to 4.2 fold higher, as in the cases of ZO-2 domain 1 and DNAM-1 in the presence of desipramine or nortryptilline and examples are listed in TABLE 10B.\n\n\nNote that the sentences extracted do not always contain a specific molecule name, ID, or other identifier, a bioactivity metric (IC50, Ki, Kd, EC50), a specific numeric value, and a unit for that value, as the text does not provide many explicit examples of these metrics. However, the extracted sentences provide some context for specific molecules, proteins, and metrics."}
{"final_json": [{"molecule_name": "CD95 8-mer", "protein_target_name": "CLASP-2", "binding_metric": null, "value": "30%", "unit": "%"}, {"molecule_name": "CD95 labeled ligand", "protein_target_name": null, "binding_metric": null, "value": "2.5 to 5-fold", "unit": null}, {"molecule_name": null, "protein_target_name": "AF6", "binding_metric": null, "value": "4.3 fold", "unit": null}, {"molecule_name": "amitriptyline", "protein_target_name": "presenilin-1", "binding_metric": null, "value": "4.3 fold", "unit": null}, {"molecule_name": null, "protein_target_name": "ZO-2 domain 1", "binding_metric": null, "value": "4.2 fold", "unit": null}, {"molecule_name": "desipramine", "protein_target_name": "DNAM-1", "binding_metric": null, "value": "4.2 fold", "unit": null}, {"molecule_name": "nortryptilline", "protein_target_name": null, "binding_metric": null, "value": null, "unit": null}]}
